T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
Conditions: Hepatocellular Carcinoma; Hepatoblastoma Interventions: Genetic: TEGAR T cells; Drug: Cytoxan; Drug: Fludarabine Sponsors: Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Carcinoma | Children | Genetics | Hepatoblastoma | Hepatocellular Carcinoma | Hospitals | Immunotherapy | Liver | Liver Cancer | Research | Urology & Nephrology